Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 2 spellings of its name, each linked to the record.
As of Nov 22, 2026, FDA's public records list Axsome Therapeutics and its 1 subsidiaries with 3 drug applications and 1 OPDP letter. The most recent is an OPDP letter dated Sep 9, 2025: Untitled letter: AUVELITY.
Group recordsLabelled by a language model (which subsidiaries belong to the group) from the firm's FDA names. It is not an FDA field.: 4, 2 entities
Drug applications: 3
OPDP letters: 1
Records by year
Drug approvals, 510(k) clearances, recalls and letters, 2019 to 2026 to date, Axsome Therapeutics and its 1 subsidiaries
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
120192019Records1
20202020Records0vs 2019−1
20212021Records0vs 2020+0
120222022Records1vs 2021+1
20232023Records0vs 2022−1
20242024Records0vs 2023+0
120252025Records1vs 2024+1
20262026 to dateRecords0
Latest records
Newest first across sources; each opens the record
6 trials since 2013, 6 ongoing, by the sponsor of the products; see every authorized trial
A multi-center, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of solriamfetol in…Aug 5, 2025 · Ongoing · Solriamfetol
A study to assess the long-term efficacy and safety of AXS-12 in the treatment of cataplexy and excessive daytime…Nov 8, 2021 · Ongoing · Reboxetine (AXS-12)
Randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of AXS-12 in the…Sep 28, 2021 · Ongoing · Reboxetine (AXS-12)
An open-label study to assess the long-term safety and efficacy of AXS-05 in subjects with dementia of the Alzheimer's…Mar 30, 2021 · Ongoing · AXS-05 (dextromethorphan-bupropion)
A double-blind, placebo-controlled, randomized withdrawal trial to assess the efficacy and safety of AXS-05 for the…Mar 29, 2021 · Ongoing · AXS-05 (dextromethorphan-bupropion)
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of AXS-02 (disodium zoledronate…Sep 14, 2015 · Ongoing · AXS-02 (zoledronate)
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $24.7M of it for research; see every company
$1.1M20222022Paid$1.1M
$9.5M20232023Paid$9.5Mvs 2022+$8.4M
$23.6M20242024Paid$23.6Mvs 2023+$14.1M
$33.3M20252025Paid$33.3Mvs 2024+$9.8M
Orphan designations (FDA)
3 designations since 1983, 1 approved for the designated use, matched by the sponsor's name; see all orphan designations
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.